Cell4Cure is a biotech company developing personalized immune tolerance therapies using ex vivo-engineered tolerogenic dendritic cells to address anti-drug antibodies, autoimmune diseases, and transplant rejection. Its lead candidate, ItolDC-028, is positioned for a Phase 1/2a trial in hemophilia A patients who have developed neutralizing antibodies against factor VIII replacement therapy. The company's platform aims to induce antigen-specific tolerance while preserving essential immune function.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Funding not disclosed
Founders
Product
Problem
Patients with conditions like severe hemophilia A often develop anti-drug antibodies (ADAs) that neutralize the effectiveness of biologic treatments such as factor VIII replacement therapy, affecting approximately 30% of patients. Autoimmune diseases and transplant rejection similarly involve unwanted immune responses that current immunosuppressive treatments manage poorly, often with significant side effects.
Solution
Cell4Cure provides a proprietary platform technology using ex vivo-engineered, autologous tolerogenic dendritic cells (tolDCs) designed to induce antigen-specific immune tolerance. The approach leverages the body's natural mechanisms for introducing tolerance, specifically targeting unwanted immune responses while preserving essential immune function. The lead product candidate, ItolDC-028, is positioned to enter a Phase 1/2a clinical trial for hemophilia A patients with ADAs against factor VIII. The platform is also offered broadly to other companies seeking to overcome immunogenicity-related therapeutic challenges across multiple disease areas.
Target Audience
Primary customers include biotechnology and pharmaceutical companies developing biologic therapies challenged by immunogenicity, as well as clinical centers treating hemophilia A patients with factor VIII inhibitors and patients with autoimmune conditions or requiring organ transplantation.
Features
- Ex vivo-generated tolerogenic dendritic cells engineered to induce antigen-specific immune tolerance
- Autologous cell therapy approach using patient-derived cells to minimize immune compatibility issues
- Patented method for generating tolDCs with U.S. patent protection extended into 2043 and additional patents granted in Japan and China
- EMA-approved clinical trial protocol for lead candidate ItolDC-028
- Established GMP manufacturing processes for robust, scalable cell production
- Platform applicable across multiple therapeutic areas including anti-drug antibodies, autoimmune diseases, and transplant rejection